Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl

Anticancer Research

Volumn 27, Issue 4 B, 2007, Pages 2253-2263

  Hosaka, Takamichi ^a,b   Inoue, Fumiko ^a   Ando, Koichi ^a   Ishida, Hiroo ^a   Kusumoto, Sojiro ^a   Sugiyama, Tomohide ^a,b   Shirai, Takao ^a   Okuda, Kentaro ^a   Hirose, Takashi ^a   Ohnishi, Tsukasa ^a   Horichi, Naoya ^a   Saijo, Nagahiro ^c   Adachi, Mitsuru ^a   Nakadate, Toshio ^b   Kuroki, Toshio ^d   Ohmori, Tohru ^a  

^a SHOWA UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d GIFU UNIVERSITY   (Japan)

Author keywords

Acquired resistance; C Cbl; Gefitinib; Mutant EGFR; Non small cell lung cancer; Tyrosine kinase inhibitor; Ubiquitin

Indexed keywords

CBL PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; IODINE 125; UBIQUITIN PROTEIN LIGASE;

ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CONTROLLED STUDY; DELETION MUTANT; EMBRYO; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFECTION; UBIQUITIN;

EID: 34547738574     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Wells A: EGF receptor. Int J Biochem Cell Biol 31(6): 637-643, 1999.
2. Yarden Y: The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4): S3-8, 2001.
3. Prenzel N, Fischer OM, Streit S, Hart S and Ullrich A: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8(1): 11-31, 2001.
4. Herbst RS: Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol 30(1 Suppl 1): 30-38, 2003.
5. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP and Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21(12): 2237-2246, 2003.
6. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ and Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama 290(16): 2149-2158, 2003.
7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21): 2129-2139, 2004.
8. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676): 1497-1500, 2004.
9. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2): 127-137, 2001.
10. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK and Milas L: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5(10): 2884-2890, 1999.
11. Authier F, Metioui M, Bell AW and Mort JS: Negative regulation of epidermal growth factor signaling by selective proteolytic mechanisms in the endosome mediated by cathepsin B. J Biol Chem 274(47): 33723-33731, 1999.
12. de Melker AA, van der Horst G, Calafat J, Jansen H and Borst J: c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytic route. J Cell Sci 114(Pt 11): 2167-2178, 2001.
13. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B and Yarden Y: c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 12(23): 3663-3674, 1998.
14. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T and Liu YC: The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286(5438): 309-312, 1999.
15. Waterman H, Levkowitz G, Alroy I and Yarden Y: The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J Biol Chem 274(32): 22151-22154, 1999.
16. Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN and Rosenfeld MG: Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science 247(4945): 962-964, 1990.
17. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N and Nishio K: Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 64(24): 9101-9104, 2004.
18. Koizumi F, Shimoyama T, Taguchi F, Saijo N and Nishio K: Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 116(1): 36-44, 2005.
19. Sorkin A, Di Fiore PP and Carpenter G: The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. Oncogene 8(11): 3021-3028, 1993.
20. Kornilova E, Sorkina T, Beguinot L and Sorkin A: Lysosomal targeting of epidermal growth factor receptors via a kinase-dependent pathway is mediated by the receptor carboxyl-terminal residues 1022-1123. J Biol Chem 271(48): 30340-30346, 1996.
21. Ando K, Ohmori T, Inoue F, Kadofuku T, Hosaka T, Ishida H, Shirai T, Okuda K, Hirose T, Horichi N, Nishio K, Saijo N, Adachi M and Kuroki T: Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. Clin Cancer Res 11(24 Pt 1): 8872-8879, 2005.
22. Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, Kaiser BK and Reimann JD: The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 10(10): 429-439, 2000.
23. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S and Yarden Y: Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4(6): 1029-1040, 1999.
24. Fukazawa T, Miyake S, Band V and Band H: Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J Biol Chem 271(24): 14554-14559, 1996.
25. Take H, Watanabe S, Takeda K, Yu ZX, Iwata N and Kajigaya S: Cloning and characterization of a novel adaptor protein, CIN85, that interacts with c-Cbl. Biochem Biophys Res Commun 268(2): 321-328, 2000.
26. Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY and Dikic I: Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 416(6877): 183-187, 2002.
27. Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N and Nishio K: In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib. Biochem J 397(3): 537-543, 2006.
28. Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305(5687): 1163-1167, 2004.
29. Akca H, Tani M, Hishida T, Matsumoto S and Yokota J: Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. Lung Cancer 54(1): 25-33, 2006.
30. Galcheva-Gargova Z, Theroux SJ and Davis RJ: The epidermal growth factor receptor is covalently linked to ubiquitin. Oncogene 11(12): 2649-2655, 1995.
31. Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, Reddi AL, Ghosh A, Fernandes N, Zhou P, Mullane-Robinson K, Rao N, Donoghue S, Rogers RA, Bowtell D, Naramura M, Gu H, Band V and Band H: Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem 278(31): 28950-28960, 2003.
32. Jiang X and Sorkin A: Epidermal growth factor receptor internalization through clathrin-coated pits requires Cbl RING finger and proline-rich domains but not receptor polyubiquitylation. Traffic 4(8): 529-543, 2003.
33. Mosesson Y, Shtiegman K, Katz M, Zwang Y, Vereb G, Szollosi J and Yarden Y: Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem 278(24): 21323-21326, 2003.
34. Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A, Jovin T and Yarden Y: A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. Embo J 21(3): 303-313, 2002.
35. Batzer AG, Rotin D, Urena JM, Skolnik EY and Schlessinger J: Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol 14(8): 5192-5201, 1994.
36. Kassenbrock CK and Anderson SM: Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations. J Biol Chem 279(27): 28017-28027, 2004.